🔎 Trials Near Me

Home › Amyloidosis › District of Columbia › Washington

Amyloidosis clinical trials in Washington, DC

5 studies for Amyloidosis are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

RecruitingObservational study
  • Research Site, Washington D.C.
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT06465810

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

RecruitingPhase 3
  • Clinical Trial Site, Washington D.C.
Ages 18 to 85 · All sexes · Updated Sep 16, 2026 · NCT07052903

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

RecruitingPhase 3
  • MedStar Washington Hospital Center - MedStar Heart and Vascular Institute, Washington D.C.
Ages 18 to 75 · All sexes · Updated Aug 4, 2026 · NCT06563895

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

RecruitingPhase 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi away
Ages 18 to 120 · All sexes · Updated May 19, 2026 · NCT06974877

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

RecruitingPhase 3
  • MedStar Washington Hospital Center - MedStar Heart and Vascular Institute, Washington D.C.
Ages 18 to 90 · All sexes · Updated Mar 27, 2026 · NCT06128629

About Amyloidosis

Amyloidosis is a rare condition that can affect different organs of the body. Find out about amyloidosis treatment and symptoms.

More about Amyloidosis on MedlinePlus

Amyloidosis trials in other cities

Other studies in Washington

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.